ThyPRO: Thyroid-Related Patient Reported Outcomes Scale
Thyroid-Related Patient Reported Outcomes Scale · Also known as: ThyPRO-85, ThyPRO-39
ThyPRO is a comprehensive patient-reported outcome measure assessing the quality of life impact of thyroid disease and its treatment across 13 dimensions. Developed by Watt and colleagues in 2009, it is the most extensively validated thyroid-specific instrument, covering both physical and psychological domains relevant to patients with hyperthyroidism, hypothyroidism, and thyroid cancer.
Read the full method
Sign in with a free account to read this section.
Method map
The neighbourhood of related methods — select a node to explore.
When to use it
ThyPRO is indicated for: (1) Monitoring quality of life in patients with Graves' disease, hashimoto thyroiditis, or thyroid cancer during treatment; (2) Research evaluating interventions for thyroid disease (thyroidectomy, radioiodine, antithyroid drugs); (3) Shared decision-making when balancing treatment intensity vs. quality of life burden; (4) Identifying patients with persistent symptom burden despite biochemical euthyroidism; (5) Evaluating long-term hypothyroid or hyperthyroid symptom persistence. Appropriate for adults aged 18+; pediatric versions under development. Used internationally in clinical trials and increasingly in routine endocrinology practice.
Strengths & limitations
- Multidimensional coverage: 13 distinct domains capture the full symptom and functional burden of thyroid disease, not collapsible to a single dimension.
- Strong psychometric evidence: Extensively validated across multiple languages and patient populations; high internal consistency (Cronbach alpha 0.80-0.95 per domain) and test-retest reliability.
- Responsiveness to clinical change: Sensitive to symptom improvement with treatment; published MCID values enable clinically meaningful difference detection in trials and practice.
- Thyroid-specific content: Developed with patient input to reflect thyroid disease-relevant concerns (e.g., cold/heat intolerance, eye symptoms in Graves' disease), missing from generic QoL measures.
- 4-week recall period may miss acute symptom fluctuations in patients with rapid mood or energy changes.
- Limited data comparing responsiveness across treatment modalities (surgical, radioiodine, pharmacological) in head-to-head prospective studies.
- Psychological domains (anxiety, irritability) show moderate-high overlap; factor structure remains under refinement in some language versions.
- Ceiling effects observed in some domains among patients with mild disease or well-controlled symptoms; may limit sensitivity in quiescent populations.
Frequently asked
Is ThyPRO-39 as reliable as ThyPRO-85?
Yes. The short form (ThyPRO-39) retains excellent psychometric properties (Cronbach alpha >0.80 per domain) with minimal loss of information compared to the full 85-item version. ThyPRO-39 is recommended for routine clinical use due to shorter administration time (10 minutes vs. 20 minutes) without sacrificing measurement validity.
What TSH target corresponds to best ThyPRO scores?
No fixed TSH threshold predicts ThyPRO response. Patients show wide variation: some achieve good quality of life at TSH 1-2 mIU/L, others report persistent fatigue and cognitive symptoms despite TSH in target range. Individual titration based on both TSH and ThyPRO domains is recommended, particularly for patients with residual hypothyroid complaints at standard TSH targets.
Can ThyPRO be used before diagnosis (screening)?
No. ThyPRO is designed for diagnosed thyroid disease patients and assesses disease-related quality of life. It is not a screening tool for thyroid dysfunction. Use TSH and thyroid antibodies for diagnostic screening.
Are there normative data for comparison to general population?
Yes. Published reference values from >2,000 Danish thyroid patients show mean domain scores by diagnosis (Graves', Hashimoto, post-thyroidectomy). General population comparisons available in peer-reviewed literature; most thyroid populations score 40-60 (moderate impact) on fatigue and emotional domains at baseline.
Sources
- Watt, T., Bjorner, J. B., Groenvold, M., et al. (2009). Establishing construct validity for the thyroid-related patient reported outcomes (ThyPRO): An initial examination. J Clin Endocrinol Metab, 94(9), 3572-3580. link ↗
- Watt, T., Groenvold, M., Bjorner, J. B., et al. (2012). Validity and responsiveness of the Danish version of ThyPRO and comparison with the Perceived Deficits Questionnaire. Value Health, 15(3), 528-534. link ↗
How to cite this page
ScholarGate. (2026, June 3). Thyroid-Related Patient Reported Outcomes Scale. ScholarGate. https://scholargate.app/en/endocrinology/thyroid-patient-reported-outcomes
Which method?
Set this method beside its closest kin and read them side by side — the library lays the books on the table; the choice is yours.
- AddiQoLEndocrinology↔ compare
- AGHDAEndocrinology↔ compare
- Diabetes Symptom ChecklistEndocrinology↔ compare